Urmila Saxena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Urmila Saxena has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Asim Bikas Das
Department of Biotechnology, National Institute of Technology Warangal
7 shared publications Jyotsna Priyam
Department of Biotechnology, National Institute of Technology Warangal, Warangal, India
3 shared publications- Pranab Goswami
Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India
3 shared publications B. Sumithra
Department of Biotechnology, National Institute of Technology Warangal, Warangal, India
2 shared publicationsV. S. P. K. Sankara Aditya Jayanthi
Department of Biotechnology, National Institute of Technology Warangal, Warangal, India
2 shared publicationsV.S.P.K. Sankara Aditya Jayanthi
Department of Biotechnology, National Institute of Technology Warangal, Warangal 506004, Telangana, India
2 shared publications
Latest Publications
- 5 May 2026
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (22) , 4668-4678
A high-performance nanohybrid impedimetric platform for early cancer detection via c-Myc oncoprotein sensing
An electrochemical nanohybrid immunosensor integrating N-doped MWCNTs and AgNPs enables ultra-sensitive, stable, point-of-care detection of Myc oncogene.
- 5 May 2026
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 18 (22) , 4668-4678
A high-performance nanohybrid impedimetric platform for early cancer detection via c-Myc oncoprotein sensing
An electrochemical nanohybrid immunosensor integrating N-doped MWCNTs and AgNPs enables ultra-sensitive, stable, point-of-care detection of Myc oncogene.
- 21 October 2023
- Published by Springer Nature in Biotechnology Letters
- Vol. 45 (11-12) , 1395-1416
Therapeutic applications of carbon nanomaterials in renal cancer
Carbon nanomaterials (CNMs), including carbon nanotubes (CNTs), graphene, and nanodiamonds (NDs), have shown great promise in detecting and treating numerous cancers, including kidney cancer. CNMs can increase the sensitivity of diagnostic techniques for better kidney cancer identification and surveillance. They enable targeted medicine delivery specifically to tumour locations, with little effect on healthy tissue. Because of their unique chemical and physical characteristics, they can avoid the body's defence mechanisms, making it easier to accumulate where tumours exist. Consequently, CNMs provide more effective drug delivery to kidney cancer cells. It also helps in improving the efficacy of treatment. This review explores the potential of several CNMs in improving therapeutic strategies for kidney cancer. We briefly covered the physicochemical properties and therapeutic applications of CNMs. Additionally, we discussed how structural modifications in CNMs enhance their precision in treating renal cancer. A thorough overview of CNM-based gene, peptide, and drug delivery strategies for the treatment of renal cancer is presented in this review. It covers information on other CNM-based therapeutic approaches, such as hyperthermia, photodynamic therapy, and photoacoustic therapy. Also, the interactions of CNMs with the tumour microenvironment (TME) are explored, including modulation of the immune response, regulation of tumour hypoxia, interactions between CNMs and TME cells, effects of TME pH on CNMs, and more. Finally, potential side effects of CNMs, such as toxicity, bio corona formation, enzymatic degradation, and biocompatibility, are also discussed.
- 21 October 2023
- Published by Springer Nature in Biotechnology Letters
- Vol. 45 (11-12) , 1395-1416
Therapeutic applications of carbon nanomaterials in renal cancer
Carbon nanomaterials (CNMs), including carbon nanotubes (CNTs), graphene, and nanodiamonds (NDs), have shown great promise in detecting and treating numerous cancers, including kidney cancer. CNMs can increase the sensitivity of diagnostic techniques for better kidney cancer identification and surveillance. They enable targeted medicine delivery specifically to tumour locations, with little effect on healthy tissue. Because of their unique chemical and physical characteristics, they can avoid the body's defence mechanisms, making it easier to accumulate where tumours exist. Consequently, CNMs provide more effective drug delivery to kidney cancer cells. It also helps in improving the efficacy of treatment. This review explores the potential of several CNMs in improving therapeutic strategies for kidney cancer. We briefly covered the physicochemical properties and therapeutic applications of CNMs. Additionally, we discussed how structural modifications in CNMs enhance their precision in treating renal cancer. A thorough overview of CNM-based gene, peptide, and drug delivery strategies for the treatment of renal cancer is presented in this review. It covers information on other CNM-based therapeutic approaches, such as hyperthermia, photodynamic therapy, and photoacoustic therapy. Also, the interactions of CNMs with the tumour microenvironment (TME) are explored, including modulation of the immune response, regulation of tumour hypoxia, interactions between CNMs and TME cells, effects of TME pH on CNMs, and more. Finally, potential side effects of CNMs, such as toxicity, bio corona formation, enzymatic degradation, and biocompatibility, are also discussed.
- Open Access
- 22 July 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Stage-specific coexpression network analysis of Myc in cohorts of renal cancer
The present study investigates the molecular dynamics of Myc in normal precursors and in different stages (I/II/III/IV) of cohorts of renal cancer using two distinct yet complementary approaches: gene expression and gene coexpression. We also analysed the variation of coexpression networks of Myc through the stage-wise progression of renal cancer cohorts. Myc expression is significantly higher in stage I compared to normal tissue but changed inconsistently across stages of renal cancer. We identified that Myc consistently coexpressed with fourteen genes in the KIPAN [Pan-kidney cohort (KICH + KIRC + KIRP)] and eight in the KIRC (Kidney renal clear cell carcinoma) across all stages, providing potential prognostic and diagnostic biomarkers. Coexpression network complexity decreased from normal precursor tissues to associated tumour stage I in KIPAN and KIRC but was inconsistent after that. In the process of cancer development, there is generally lower cross-tissue cancer network homology observed among coexpressed genes with Myc during the normal to the stage I compared to the stage-wise progression of cancer. Overall, this research provides novel perceptions of the molecular causes of kidney cancer. It also highlights potential genes and pathways crucial for diagnosing and treating this disease.
- 22 July 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessStage-specific coexpression network analysis of Myc in cohorts of renal cancer
The present study investigates the molecular dynamics of Myc in normal precursors and in different stages (I/II/III/IV) of cohorts of renal cancer using two distinct yet complementary approaches: gene expression and gene coexpression. We also analysed the variation of coexpression networks of Myc through the stage-wise progression of renal cancer cohorts. Myc expression is significantly higher in stage I compared to normal tissue but changed inconsistently across stages of renal cancer. We identified that Myc consistently coexpressed with fourteen genes in the KIPAN [Pan-kidney cohort (KICH + KIRC + KIRP)] and eight in the KIRC (Kidney renal clear cell carcinoma) across all stages, providing potential prognostic and diagnostic biomarkers. Coexpression network complexity decreased from normal precursor tissues to associated tumour stage I in KIPAN and KIRC but was inconsistent after that. In the process of cancer development, there is generally lower cross-tissue cancer network homology observed among coexpressed genes with Myc during the normal to the stage I compared to the stage-wise progression of cancer. Overall, this research provides novel perceptions of the molecular causes of kidney cancer. It also highlights potential genes and pathways crucial for diagnosing and treating this disease.
- 23 January 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 195 (7) , 4251-4276
Computational Gene Expression and Network Analysis of Myc Reveal Insights into Its Diagnostic and Prognostic Role in Subtypes of Renal Cancer
In this study, we analysed the Myc expression in the pan-kidney cohort (KIPAN) and kidney renal clear cell carcinoma (KIRC) in human tumour tissues compared to normal tissues. Myc is overexpressed and associated with poor overall survival (OS) in the KIPAN and KIRC. It shows that Myc plays a crucial role in the growth and maintenance of these malignancies. Additionally, we explored coexpressed genes, gene-set enrichment analysis of coexpressed genes, proteins and regulatory partners directly linked with Myc in KIPAN and KIRC and their role in cancer-specific events. Pathway enrichment analysis concluded that Myc-related genes are involved in many cancer-related pathways. Furthermore, we studied that among KIPAN, mutant forms of tumour suppressor genes have a poor prognosis and are associated with higher Myc expression but not in KIRC. This paper also investigates the correlation between Myc expression and promoter methylation, tumour-infiltrating lymphocytes, and the interaction of Myc with drugs. Our study indicates that Myc can be used as a diagnostic and prognostic biomarker in patients with KIPAN and KIRC with diverse clinical and pathological characteristics. Graphical Abstract
- 23 January 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 195 (7) , 4251-4276
Computational Gene Expression and Network Analysis of Myc Reveal Insights into Its Diagnostic and Prognostic Role in Subtypes of Renal Cancer
In this study, we analysed the Myc expression in the pan-kidney cohort (KIPAN) and kidney renal clear cell carcinoma (KIRC) in human tumour tissues compared to normal tissues. Myc is overexpressed and associated with poor overall survival (OS) in the KIPAN and KIRC. It shows that Myc plays a crucial role in the growth and maintenance of these malignancies. Additionally, we explored coexpressed genes, gene-set enrichment analysis of coexpressed genes, proteins and regulatory partners directly linked with Myc in KIPAN and KIRC and their role in cancer-specific events. Pathway enrichment analysis concluded that Myc-related genes are involved in many cancer-related pathways. Furthermore, we studied that among KIPAN, mutant forms of tumour suppressor genes have a poor prognosis and are associated with higher Myc expression but not in KIRC. This paper also investigates the correlation between Myc expression and promoter methylation, tumour-infiltrating lymphocytes, and the interaction of Myc with drugs. Our study indicates that Myc can be used as a diagnostic and prognostic biomarker in patients with KIPAN and KIRC with diverse clinical and pathological characteristics. Graphical Abstract
- 29 November 2022
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 195 (5) , 2917-2932
Integrative Analysis of Potential Biomarkers Involved in the Progression of Papillary Thyroid Cancer
This study aims to explore key prognostic and diagnostic biomarkers involved in the pathogenesis of papillary thyroid cancer (PTC) which is one of the most common endocrine cancers and whose occurrence is rapidly increasing. Papillary thyroid cancer datasets containing normal and tumor samples were collected from Gene Expression Omnibus. Protein–protein interaction (PPI) network for common upregulated differentially expressed genes (DEGs) was constructed, and hub genes were studied. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were performed to identify the vital biological behaviors and pathways involved in PTC. PPI network analysis demonstrated the interaction between 134 common upregulated DEGs, and top 15 pivotal genes with highest degree of connectivity were retrieved. Three of the hub genes (DPP4, ITGA2, FN1) were linked to the prognosis of PTC patients and considered clinically relevant core genes via survival analysis. We suggest that the identification of key genes associated with PTC development help us in understanding molecular mechanisms related to disease. These genes could also be considered the diagnostic biomarkers or as therapeutic targets in the future treatment for PTC.
- 29 November 2022
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 195 (5) , 2917-2932
Integrative Analysis of Potential Biomarkers Involved in the Progression of Papillary Thyroid Cancer
This study aims to explore key prognostic and diagnostic biomarkers involved in the pathogenesis of papillary thyroid cancer (PTC) which is one of the most common endocrine cancers and whose occurrence is rapidly increasing. Papillary thyroid cancer datasets containing normal and tumor samples were collected from Gene Expression Omnibus. Protein–protein interaction (PPI) network for common upregulated differentially expressed genes (DEGs) was constructed, and hub genes were studied. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were performed to identify the vital biological behaviors and pathways involved in PTC. PPI network analysis demonstrated the interaction between 134 common upregulated DEGs, and top 15 pivotal genes with highest degree of connectivity were retrieved. Three of the hub genes (DPP4, ITGA2, FN1) were linked to the prognosis of PTC patients and considered clinically relevant core genes via survival analysis. We suggest that the identification of key genes associated with PTC development help us in understanding molecular mechanisms related to disease. These genes could also be considered the diagnostic biomarkers or as therapeutic targets in the future treatment for PTC.
- 9 July 2020
- Published by Springer Nature in Biotechnology Letters
- Vol. 42 (12) , 2501-2509
Antibody-based biosensor to detect oncogenic splicing factor Sam68 for the diagnosis of lung cancer
Objective The present work aimed to investigate the potential utility of Sam68 protein as a prognostic marker in lung cancer. Then an electrochemical immunosensor is fabricated that is sufficiently sensitive to detect Sam68. Results Analysis of stage-specific Lung cancer microarray data shows that differential expression of Sam68 is associated with cancer stage and monotonically increases from early tumor stage to advanced metastatic stage. Moreover, the higher expression of Sam68 results in reduced survival of lung cancer patients. Based on these observations, an electrochemical immunosensor was developed for the quantification of Sam68 protein. The target protein was captured by the Anti-Sam68 antibody that was immobilized on the modified Glassy carbon electrode. The stepwise assembly process was characterized by cyclic voltammetry and electrochemical impedance spectroscopy. This fabricated immunosensor displayed good analytical performance in comparison to commercial ELISA kit with good sensitivity, lower detection limit (LOD) of 10.5 pg mL−1, and wide linear detection range from 1 to 5 μg mL−1. This method was validated with satisfactory detection of Sam68 protein in lung adenocarcinoma cell line, NCI-H23. Besides, spike and recovery assay reconfirm that the sensor can precisely quantify Sam68 protein in a complex physiological sample. Conclusion We conclude Sam68 as a valuable prognostic biomarker for early detection of lung cancer. Moreover, we report the first study on the development of an electrochemical immunosensor for the detection of Sam68. The fabricated immunosensor exhibit excellent analytical performance, which can accurately predict the lung cancer patient pathological state.
- 9 July 2020
- Published by Springer Nature in Biotechnology Letters
- Vol. 42 (12) , 2501-2509
Antibody-based biosensor to detect oncogenic splicing factor Sam68 for the diagnosis of lung cancer
Objective The present work aimed to investigate the potential utility of Sam68 protein as a prognostic marker in lung cancer. Then an electrochemical immunosensor is fabricated that is sufficiently sensitive to detect Sam68. Results Analysis of stage-specific Lung cancer microarray data shows that differential expression of Sam68 is associated with cancer stage and monotonically increases from early tumor stage to advanced metastatic stage. Moreover, the higher expression of Sam68 results in reduced survival of lung cancer patients. Based on these observations, an electrochemical immunosensor was developed for the quantification of Sam68 protein. The target protein was captured by the Anti-Sam68 antibody that was immobilized on the modified Glassy carbon electrode. The stepwise assembly process was characterized by cyclic voltammetry and electrochemical impedance spectroscopy. This fabricated immunosensor displayed good analytical performance in comparison to commercial ELISA kit with good sensitivity, lower detection limit (LOD) of 10.5 pg mL−1, and wide linear detection range from 1 to 5 μg mL−1. This method was validated with satisfactory detection of Sam68 protein in lung adenocarcinoma cell line, NCI-H23. Besides, spike and recovery assay reconfirm that the sensor can precisely quantify Sam68 protein in a complex physiological sample. Conclusion We conclude Sam68 as a valuable prognostic biomarker for early detection of lung cancer. Moreover, we report the first study on the development of an electrochemical immunosensor for the detection of Sam68. The fabricated immunosensor exhibit excellent analytical performance, which can accurately predict the lung cancer patient pathological state.
- Open Access
- 29 May 2019
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 9 (29) , 16738-16745
Fabrication of an immunosensor for quantitative detection of breast cancer biomarker UBE2C
This work reports the design of a new electrochemical impedimetric immunosensor for the direct determination of ubiquitin-conjugating enzymes 2C (UBE2C), a potential diagnostic biomarker for breast cancer. The immunosensor was fabricated by immobilizing the capture anti-UBE2C antibody onto a polyaniline (PANI) modified glassy carbon electrode (GCE) through glutaraldehyde crosslinking. The assembly process of the immunosensor was examined using scanning electron microscopy, cyclic voltammetry, and electrochemical impedance spectroscopy. The fabricated immunosensor enabled the detection of recombinant human UBE2C in the range of 500 pg mL−1 to 5 μg mL−1. The limit of detection and limit of quantification were found to be 7.907 pg mL−1 and 26.356 pg mL−1, respectively. The diagnostic application of the fabricated immunosensor was explored for the analysis of breast cancer cell line MCF-7 cell extract. The immunosensor demonstrated high selectivity for UBE2C. The fabricated immunosensor also exhibited good reproducibility and storage stability.
- 29 May 2019
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 9 (29) , 16738-16745
Open AccessFabrication of an immunosensor for quantitative detection of breast cancer biomarker UBE2C
This work reports the design of a new electrochemical impedimetric immunosensor for the direct determination of ubiquitin-conjugating enzymes 2C (UBE2C), a potential diagnostic biomarker for breast cancer. The immunosensor was fabricated by immobilizing the capture anti-UBE2C antibody onto a polyaniline (PANI) modified glassy carbon electrode (GCE) through glutaraldehyde crosslinking. The assembly process of the immunosensor was examined using scanning electron microscopy, cyclic voltammetry, and electrochemical impedance spectroscopy. The fabricated immunosensor enabled the detection of recombinant human UBE2C in the range of 500 pg mL−1 to 5 μg mL−1. The limit of detection and limit of quantification were found to be 7.907 pg mL−1 and 26.356 pg mL−1, respectively. The diagnostic application of the fabricated immunosensor was explored for the analysis of breast cancer cell line MCF-7 cell extract. The immunosensor demonstrated high selectivity for UBE2C. The fabricated immunosensor also exhibited good reproducibility and storage stability.
- Top Cited Papers
- 1 May 2017
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 91, 15-23
Recent advances in biosensor development for the detection of cancer biomarkers
- 1 May 2017
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 91, 15-23
Top Cited PapersRecent advances in biosensor development for the detection of cancer biomarkers
- 13 January 2016
- Published by Springer Nature in Cellular Oncology
- Vol. 39 (1) , 1-13
Alternative splicing within the Wnt signaling pathway: role in cancer development
Background The Wnt signaling cascade plays a fundamental role in embryonic development, adult tissue regeneration, homeostasis and stem cell maintenance. Abnormal Wnt signaling has been found to be prevalent in various human cancers. Also, a role of Wnt signaling in the regulation of alternative splicing of several cancer-related genes has been established. In addition, accumulating evidence suggests the existence of multiple splice isoforms of Wnt signaling cascade components, including Wnt ligands, receptors, components of the destruction complex and transcription activators/suppressors. The presence of multiple Wnt signaling-related isoforms may affect the functionality of the Wnt pathway, including its deregulation in cancer. As such, specific Wnt pathway isoform components may serve as therapeutic targets or as biomarkers for certain human cancers. Here, we review the role of alternative splicing of Wnt signaling components during the onset and progression of cancer. Conclusions Splice isoforms of components of the Wnt signaling pathway play distinct roles in cancer development. Isoforms of the same component may function in a tissue- and/or cancer-specific manner. Splice isoform expression analyses along with deregulated Wnt signaling pathway analyses may be of help to design efficient diagnostic and therapeutic strategies.
- 13 January 2016
- Published by Springer Nature in Cellular Oncology
- Vol. 39 (1) , 1-13
Alternative splicing within the Wnt signaling pathway: role in cancer development
Background The Wnt signaling cascade plays a fundamental role in embryonic development, adult tissue regeneration, homeostasis and stem cell maintenance. Abnormal Wnt signaling has been found to be prevalent in various human cancers. Also, a role of Wnt signaling in the regulation of alternative splicing of several cancer-related genes has been established. In addition, accumulating evidence suggests the existence of multiple splice isoforms of Wnt signaling cascade components, including Wnt ligands, receptors, components of the destruction complex and transcription activators/suppressors. The presence of multiple Wnt signaling-related isoforms may affect the functionality of the Wnt pathway, including its deregulation in cancer. As such, specific Wnt pathway isoform components may serve as therapeutic targets or as biomarkers for certain human cancers. Here, we review the role of alternative splicing of Wnt signaling components during the onset and progression of cancer. Conclusions Splice isoforms of components of the Wnt signaling pathway play distinct roles in cancer development. Isoforms of the same component may function in a tissue- and/or cancer-specific manner. Splice isoform expression analyses along with deregulated Wnt signaling pathway analyses may be of help to design efficient diagnostic and therapeutic strategies.